Is ‘BerkshAmazMorgan’ Testing a Cure for What Ails US Healthcare?

Posted by Pratap Khedkar on Thu, Mar 29, 2018

Paul Darling co-wrote this blog post with Pratap Khedkar.

This is the second post in a two-part series on the recently announced Berkshire Hathaway/Amazon/JPMorgan Chase healthcare venture. 

The U.S. healthcare system is broken. Most healthcare stakeholders now are willing to admit that, and many are actively trying to fix it—or at least starting to talk about what it would take to do so. Many of the recent consolidations and vertical integrations are the involved parties’ attempts at solving for links in the healthcare chain that they previously had no access to, or influence over. Now three giants from corporate America are looking to wade deeper into healthcare delivery to see if they can make some fixes for their employees—and for themselves.


>
Read More

What’s ‘BerkshAmazMorgan’ Really Capable Of?

Posted by Howard Deutsch on Tue, Feb 20, 2018

Bill Coyle, Paul Darling and Pratap Khedkar co-authored this post with Howard Deutsch.

This is the first post in a two-part series on the recently announced Berkshire Hathaway/Amazon/JPMorgan Chase healthcare venture. 

Look! Out in the distance! What’s that creature that’s destroying everything in its path? Why, it’s the scariest three-headed monster this side of Cerberus! It’s… it’s… it’s BerkshAmazMorgan! Will any of us be safe from this dreaded, rampaging beast?


>
Read More

Reinvent Your Commercial Strategy With an ‘Outside-In’ Approach

Posted by ZS Editors on Fri, Feb 09, 2018

It used to be that pharma companies could start with the new drugs—their inventions—when planning their go-to-market strategies, but that inside-out approach doesn’t work in an increasingly customer-centric marketplace. It’s time for drug manufacturers to transition from their inside-out business models to an outside-in approach, realigning their structures and rethinking their research and resources to better assess and adapt to the changing healthcare ecosystem, and to better meet their stakeholders’ evolving needs.


>
Read More

AI Will Usher in ‘Dramatic’ Changes to Pharma’s Commercial Model

Posted by Pratap Khedkar on Thu, Jan 18, 2018

This is the second post in a three-part series on artificial intelligence in healthcare. 

Artificial intelligence is poised to revolutionize the healthcare ecosystem. Providers are starting to apply AI in an effort to leverage patient data, therapy information and standards of care to make better treatment decisions. Payers are experimenting with AI to help with pre-authorization and claims adjudication. Whether or not the pharma industry is ready, AI is changing the way that pharma’s customers and stakeholders do business, thereby necessitating changes to pharma’s own commercial practices. And, according to my colleague John Piccone, those changes will be “dramatic.”


>
Read More

The CVS/Aetna Effect: How Pharma Can Prepare for Change

Posted by Paul Darling on Thu, Dec 21, 2017

CVS Health’s proposed purchase of Aetna and UnitedHealth Group’s plan to buy DaVita’s primary care units could bring a sea change for healthcare delivery. They are two examples of the corporatization of healthcare delivery and the broader evolution of the healthcare landscape that’s currently under way. In addition to securing the position of immediate care facilities and pharmacies as first-line healthcare providers—which is expected to continue to reframe the healthcare delivery model as we know it—these deals would affect all corners of the healthcare ecosystem in areas from data and analytics to drug pricing and pharmaceutical customer influence.


>
Read More